Core Points - Hemogenyx Pharmaceuticals plc has issued a total of 123,377 new Ordinary Shares for various reasons, including the exercise of warrants and the vesting of Restricted Stock Units [2][4] - The company raised £190,000 through the exercise of warrants for 105,556 new Ordinary Shares at an exercise price of £1.80 [3] - A total of 6,000 new Ordinary Shares were issued following the vesting of Restricted Stock Units [4] - Additionally, 11,821 new Ordinary Shares were issued under a Deed of Variation at a price of £8.84 per share [5] - The total number of issued shares will reach 6,041,255 upon admission of the new shares, which will be used for shareholder calculations regarding interest notifications [7] - The new shares will be admitted to the FCA official list and trading on the LSE main market, expected around 8:00 a.m. on December 23, 2025 [6] Company Overview - Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical group focused on developing new medicines and treatments for blood and autoimmune diseases [11] - The company is developing several distinct and complementary product candidates, along with platform technologies for novel product development [11]